TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06398925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCT461201 50 mg
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCT461201 100 mg
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCT461201 150 mg
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCT461201 450 mg
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule
Study: NCT05688241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donor-derived ex-vivo expanded EBV Tscm CTL
Description: Cryopreserved cells will be thawed and infused at three time points. Dosing will be 2x10e6 EBV CTLs per kg of body weight. No prior lymphodepletion will be performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donor-derived ex-vivo expanded EBV Tscm CTL
Description: Cryopreserved cells will be thawed and infused at three time points. Dosing will be 2x10e6 EBV CTLs per kg of body weight. No prior lymphodepletion will be performed.
Study: NCT06398925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study: NCT06303856

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Breathing Exercises
Description: Active breathing exercises aim to enhance the strength and flexibility of respiratory muscles through a series of exercises, improving breathing patterns and increasing respiratory efficiency. The following are common components of active breathing exercises: 1) Deep Breathing. 2) Chest Expansion. 3) Diaphragmatic Breathing. 4) Coughing Techniques. 5) Expiratory Resistance Training. 6) Gradual Increase in Activity.
Study: NCT06258096

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LX2.3 Laser and LED Photobiomodulation System
Description: The LX2.3 Laser and LED Photobiomodulation system by THOR Photomedicine Ltd is a CE marked product and has a long track record of safety, usability, and effectiveness.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: LX2.3 Laser and LED Photobiomodulation System Sham-PBMT Setting
Description: The sham setting consists of light of the same colour (white light with a red filter), applied in the same way as in the experimental group.
Study: NCT05211713

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Opp
Description: Opp is a universal mental health promoting mobile application for adolescents aged 13-25 years.
Study: NCT05177432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QPOP
Description: QPOP will be used as a clinical decision support platform to identity suitable patient-specific drug combinations across a range of breast cancer patients, which are derived from drug sensitivity tests using patient-derived materials.
Study: NCT04594525

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Intensity Psychosocial Interventions through Telemental health
Description: Low-Intensity Psychosocial Interventions through Telemental health (Thinking healthy): The intervention will include six sessions. Each session may last to 45 min as a max, and it will be provided through telehealth. The first session will be an introduction, while the other five sessions will be covering the period from the second pregnancy trimester to the first year of the infant's life.
Study: NCT05270954

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Betuvax-CoV-2
Description: Vaccine: Betuvax-CoV-2 intramuscular injection solution (0.5 ml)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Betuvax-CoV-2
Description: Vaccine: Betuvax-CoV-2 intramuscular injection solution (0.5 ml)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Betuvax-CoV-2
Description: Vaccine: Betuvax-CoV-2 intramuscular injection solution (0.5 ml)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Betuvax-CoV-2
Description: Vaccine: Betuvax-CoV-2 intramuscular injection solution (0.5 ml)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: a 0.9% NaCl intramuscular injection solution (0.5 ml)
Study: NCT05822349

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: picograms-enriched label
Description: The intervention care includes usual care (instructions for using each anti-diabetic drug) plus pictograms that show how much medications should be taken at each time of day (morning, noon, evening, and night), how to take them in relation to meals, the purpose of the drug, and the most important non-pharmacologic interventions for diabetic patients (weight loss, exercise, avoiding smoking, blood sugar controlling).
Study: NCT06189222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality glasses
Description: The population of the study consisted of children who were aged between 7- 12 and were on treatment using an intravenous catheter in the pediatric emergency unit of a state hospital in Turkey.Participants were divided into two groups, namely experimental and control groups, by using simple randomization software. The design and implementation of the study were based on the principles in the CONSORT list (Consolidated Standards of Reporting Studies). Descriptive data form for children,this form was prepared to collect information about the children included in the sample. It consists of seven questions on children's sociodemographic characteristics and previous intravenous catheter insertion experience.The Children's Emotional Manifestation Scale (CEMS), this scale was developed by Li \& Lopez (2005) to measure children's emotional responses during stressful medical procedures. The VR glasses we used in our study were connected to a mobile phone.
Study: NCT05584865

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital occluar prosthesis
Description: Each patient will receive the full digital fabricated ocular prosthesis. DICOM data from the Computerized Tomography (CT) will be imported into Materializes Interactive Medical Image Control System (MIMICS) software++++ tool for visualizing and segmenting medical images (such as CT and MRI)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional occluar prosthesis
Description: An accurate impression of the patient's eye socket will be obtained to prepare a suitable wax mod. The wax model will be flasked and processed into heat cured acrylic resin of the same colour of the sclera of the other healthy eye of the patient
Study: NCT05696912

Intervention type: GENETIC
Group type: OTHER
Intervention: Ex-vivo approach concerning 25 patients
Description: Ex-vivo approach concerning 25 patients with blood sample in PAXgene tubes or skin biopsy and RNA-Seq analysis

Intervention type: GENETIC
Group type: OTHER
Intervention: In-vitro approach concerning 25 patients
Description: In-vitro approach concerning 25 patients without specific samples needed for analysis in minigene or luciferase assay
Study: NCT04822389

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehablitation using heart rate monitor
Description: Eligible participants will undergo 12 weeks of physical exercise using a heart rate monitor and internet platform at home. The participants will regularly (minimum once per week) upload the exercise data from the heart rate monitor into the internet platform. An exercise telerehabilitation session consists of the warm-up phase, aerobic phase (30 - 50 minutes gradually increasing exercise duration; heart rate zone based on baseline cardiopulmonary exercise test) and cool-down phase. The exercise training period is set to 3 times a week for 12 weeks. Study participants will receive user guides developed by research team with detailed instructions regarding equipment set-up, training protocol, and contact information. Also, participants will receive weekly phone calls from week 0 to week 12 to monitor adverse events, encourage compliance and adherence to the study protocol, address any subject questions or concerns, and collect information regarding participants' current symptomatology.
Study: NCT04718883

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
Description: JWCAR029 will be administered at dose level: 1 x 10\^8 CAR+T cells
Study: NCT05465850

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Modified USPHS criteria
Description: It assess the restorations with visual inspection using a mirror and explorer. It includes Marginal integrity, shade matching, retention, marginal discoloration, gingival inflammation, and recurrent caries.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Modified USPHS criteria
Description: It assess the restorations with visual inspection using a mirror and explorer. It includes Marginal integrity, shade matching, retention, marginal discoloration, gingival inflammation, and recurrent caries.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Modified USPHS criteria
Description: It assess the restorations with visual inspection using a mirror and explorer. It includes Marginal integrity, shade matching, retention, marginal discoloration, gingival inflammation, and recurrent caries.
Study: NCT05359575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio kit
Description: MP3 audio files for each of 6 steps of c-collar application (totaling 1 minute, 19 seconds) and instructional flashcard with seven pictures corresponding to each of the 6 steps of c-collar application

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio kit
Description: MP3 audio files for each of 6 steps of c-collar application (totaling 1 minute, 19 seconds) and instructional flashcard with seven pictures corresponding to each of the 6 steps of c-collar application

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio kit
Description: MP3 audio files for each of 6 steps of c-collar application (totaling 1 minute, 19 seconds) and instructional flashcard with seven pictures corresponding to each of the 6 steps of c-collar application

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instructional flashcard (version 1)
Description: Single page with 7 pictures corresponding to each of the 6 steps of cervical collar (c-collar) application.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instructional flashcard (version 1)
Description: Single page with 7 pictures corresponding to each of the 6 steps of cervical collar (c-collar) application.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-person training
Description: 10 minute of an LFR spinal immobilization course (extracted from the current LFR Level 1 trauma course).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-person training
Description: 10 minute of an LFR spinal immobilization course (extracted from the current LFR Level 1 trauma course).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instructional flashcard (version 2)
Description: Single page with 7 pictures corresponding to each of the 6 steps of cervical collar (c-collar) application edited for clarity based on initial pilot feedback.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instructional flashcard (version 2)
Description: Single page with 7 pictures corresponding to each of the 6 steps of cervical collar (c-collar) application edited for clarity based on initial pilot feedback.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instructional flashcard (version 2)
Description: Single page with 7 pictures corresponding to each of the 6 steps of cervical collar (c-collar) application edited for clarity based on initial pilot feedback.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instructional flashcard (version 2)
Description: Single page with 7 pictures corresponding to each of the 6 steps of cervical collar (c-collar) application edited for clarity based on initial pilot feedback.
Study: NCT05454826

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 1st group (n=15) relaxation exercises, 2nd group (n=15) relaxation exercises+cold compression. The exercise program will be applied for 6 weeks, 3 days a week \* 45 minutes. Relaxation exercises will be applied to the patients 3 days a week using web-based methods (Zoom).
Study: NCT05454826

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Application
Description: 1st group (n=15) relaxation exercises, 2nd group (n=15) relaxation exercises+cold compression. The exercise program will be applied for 6 weeks, 3 days a week \* 45 minutes. Relaxation exercises will be applied to the patients 3 days a week using web-based methods (Zoom).
Study: NCT05071885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: games based exercise
Description: Range of motion and strengthening exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: games based exercise
Description: Range of motion and strengthening exercises
Study: NCT04038515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine 0 mg/mL
Description: E-liquid containing no nicotine (0 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine 0 mg/mL
Description: E-liquid containing no nicotine (0 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine 0 mg/mL
Description: E-liquid containing no nicotine (0 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine 0 mg/mL
Description: E-liquid containing no nicotine (0 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine 6 mg/mL
Description: E-liquid containing low nicotine (6 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine 6 mg/mL
Description: E-liquid containing low nicotine (6 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine 6 mg/mL
Description: E-liquid containing low nicotine (6 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine 6 mg/mL
Description: E-liquid containing low nicotine (6 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine 12 mg/mL
Description: E-liquid containing medium nicotine ( 12 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
Study: NCT05658380

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atropine
Description: patients will receive 0.01 mg/kg intravenous atropine in 5 ml normal saline 0.9 % before induction of spinal anaesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: patients will receive the same volume of isotonic saline 0.9% 5ml (control group) before induction of spinal anaesthesia
Study: NCT05550441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: The experimental group received dapagliflozin (10 mg qd) for 1 year.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The Placebo group received placebo for 1 year.
Study: NCT06371950

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Formula Bacillus subtilis
Description: 5 billion colony forming units (CFU) per day for 9 weeks (3 weeks before surgery to six weeks after surgery)
Study: NCT04364620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-16B5
Description: AB-16B5 is an inhibitor of the epithelial to mesenchymal transition. It is a fully humanized monoclonal antibody of IgG2 isotype against tumor-associated secreted clusterin (TA-sCLU).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel is an anticancer chemotherapy drug approved in the treatment of non-small cell lung cancer
Study: NCT04958746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofol
Description: intravenous bolus

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: intravenous bolus
Study: NCT05228561

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Application Supported Nutrition and Diabetes Education
Description: With this intervention, the difference between the mobile application supported nutrition diabetes education created with written and visual (video) and face-to-face nutrition and diabetes education will be found.
Study: NCT06103994

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multistrain probiotic
Description: Multistrain Probiotic
Study: NCT06371950

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04843696

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: breathing training, and an educational program (relaxation techniques and a home pacing walking exercise)
Description: breathing training, and an educational program (relaxation techniques and a home pacing walking exercise) Breathing training consisted of breathing techniques (pursued-lipped, controlled, and diaphragmatic breathing)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: breathing training, and an educational program (relaxation techniques and a home pacing walking exercise)
Description: breathing training, and an educational program (relaxation techniques and a home pacing walking exercise) Breathing training consisted of breathing techniques (pursued-lipped, controlled, and diaphragmatic breathing)
Study: NCT06103994

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05338879

Intervention type: OTHER
Intervention: Non-Interventional
Description: No study treatment will be administered on this study.
Study: NCT05432479

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Single strain probiotic in a form of a sachets with a daily dose of 1.0E+9 Colony Forming Unit (CFU) per day for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05284916

Intervention type: BEHAVIORAL
Intervention: liver diseases admissions
Description: The different patterns of liver disease related admissions after the era of DAAS
Study: NCT05150210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic-Assisted Surgery
Description: da Vinci SP Surgical System, instruments, and accessories in pulmonary lobectomy and thymectomy for benign and malignant disease.
Study: NCT04038515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine 12 mg/mL
Description: E-liquid containing medium nicotine ( 12 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine 12 mg/mL
Description: E-liquid containing medium nicotine ( 12 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
Study: NCT05116696

Intervention type: PROCEDURE
Intervention: For chronic limb-threatening ischemia (CLTI) patients revascularisation surgery; for colorectal liver metastasis (CRLM) patients metastatic liver surgery
Description: For chronic limb-threatening ischemia (CLTI) patients that represents one of the revascularisation methods (endovascular, open surgery, hybrid).~For the colorectal liver metastasis (CRLM) patients that represents liver resection with adjuvant chemo- or radiotherapy

Intervention type: PROCEDURE
Intervention: For chronic limb-threatening ischemia (CLTI) patients revascularisation surgery; for colorectal liver metastasis (CRLM) patients metastatic liver surgery
Description: For chronic limb-threatening ischemia (CLTI) patients that represents one of the revascularisation methods (endovascular, open surgery, hybrid).~For the colorectal liver metastasis (CRLM) patients that represents liver resection with adjuvant chemo- or radiotherapy
Study: NCT04740697

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment requiring adjuvant Hormonal Therapy (HT) with tamoxifen.
Description: Each included patient will be referred to the health care staff for a blood sample:~* for the determination of the residual plasma concentration of tamoxifen and its active metabolites,~* for the constitution of a biobank.~Patients will then complete a questionnaire to collect information on tamoxifen intake and adherence (via the GIRERD questionnaire), as well as possible Alternative and Complementary Therapeutics (ACT) intake (reason for use, type of ACT, ...).
Study: NCT04038515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine 12 mg/mL
Description: E-liquid containing medium nicotine ( 12 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine 24 mg/mL
Description: E-liquid containing high nicotine ( 24 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).